131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat

PHASE2CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

February 26, 2021

Study Completion Date

February 26, 2021

Conditions
Neuroblastoma
Interventions
RADIATION

131I-MIBG

DRUG

Vincristine

DRUG

Irinotecan

DRUG

Vorinostat

Trial Locations (14)

27599

University of North Carolina, Chapel Hill

30322

AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta

48109

C.S Mott Children's Hospital, Ann Arbor

60637

University of Chicago, Comer Children's Hospital, Chicago

76104

Cook Children's Healthcare System, Fort Worth

80045

Children Hospital of Colorado, Aurora

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

94304

Lucile Salter Packer Children's Hospital, Palo Alto

98105

Seattle Children's Hospital, Seattle

90027-0700

Childrens Hospital Los Angeles, Los Angeles

02115

Children's Hospital Boston, Boston

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

19104-4318

Children's Hospital of Philadelphia, Philadelphia

M5G1X8

Hospital for Sick Children, Toronto

All Listed Sponsors
lead

New Approaches to Neuroblastoma Therapy Consortium

OTHER

NCT02035137 - 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat | Biotech Hunter | Biotech Hunter